SCHEMBL30133041

SCHEMBL30133041

Fc1cc(F)cc(-c2cnc3cn[nH]c3c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.50
FGFR1 P11362 3/20 0.43
FGFR2 P21802 2/20 0.43
GRIN2B Q13224 8/20 0.40
GRIN1 Q05586 2/20 0.40
PIK3CG P48736 1/20 0.39
METAP2 P50579 2/20 0.38
NOTUM Q6P988 1/20 0.38
MAOB P27338 1/20 0.37
CDK2 P24941 2/20 0.35
CCNA1 P78396 1/20 0.35
PLK4 O00444 1/20 0.35
CHEK1 O14757 1/20 0.35
PDPK1 O15530 1/20 0.35
DYRK3 O43781 1/20 0.35
JAK2 O60674 1/20 0.35
ROCK2 O75116 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29901505 0.86 DYRK1A (0.41) DYRK1AFGFR1FGFR2GRIN2BGRIN1
SCHEMBL30133018 0.85 PDGFRB (0.48) DYRK1AFGFR1FGFR2GRIN2BGRIN1
SCHEMBL30133033 0.84 DYRK1A (0.49) DYRK1AFGFR1FGFR2GRIN2BGRIN1
SCHEMBL17754852 0.84 DYRK1A (0.49) DYRK1AFGFR1FGFR2GRIN2BGRIN1
SCHEMBL29525098 0.84 DYRK1A (0.49) DYRK1AFGFR1FGFR2GRIN2BGRIN1
SCHEMBL17754953 0.84 DYRK1A (0.49) DYRK1AFGFR1FGFR2GRIN2BGRIN1
SCHEMBL2730228 0.79 DYRK1A (0.59) DYRK1AFGFR1FGFR2METAP2CHEK1
SCHEMBL17754955 0.79 DYRK1A (0.50) DYRK1AFGFR1PIK3CGMETAP2MAOB
SCHEMBL30133030 0.78 PDGFRB (0.48) DYRK1AFGFR1FGFR2GRIN2BGRIN1
SCHEMBL30327246 0.77 FGFR1 (0.47) DYRK1AFGFR1FGFR2GRIN2BMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136598-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2025-05-01 US disclosed
US-12172997-B2 Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-12-24 US disclosed
US-20230151006-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-05-18 US disclosed
US-11618750-B2 Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 US disclosed
US-20220324860-A1 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12172997-B2 Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN3A DYRK1A 2657/4885FGFR1 739/4885FGFR2 939/4885
US-20230151006-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR GRIN2B, GRIN2A, GRIN3A DYRK1A 2728/4885FGFR1 621/4885FGFR2 775/4885
US-20220324860-A1 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN3B, GRIN3A DYRK1A 2525/4885FGFR1 973/4885FGFR2 1116/4885
US-20250136598-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN3A DYRK1A 2657/4885FGFR1 739/4885FGFR2 939/4885
US-11618750-B2 Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN3A DYRK1A 2657/4885FGFR1 739/4885FGFR2 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.